
Clover Health Investments, Corp.
NASDAQ•CLOV
CEO: Mr. Vivek Garipalli
セクター: Healthcare
業種: Medical - Healthcare Plans
上場日: 2020-06-12
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
連絡先情報
時価総額
$1.04B
PER (TTM)
-17.8
0
配当利回り
--
52週高値
$4.80
52週安値
$2.01
52週レンジ
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025
財務ダッシュボード
Q3 2025 データ
売上高
$496.65M+50.05%
直近4四半期の推移
EPS
-$0.05+154.01%
直近4四半期の推移
フリーCF
$11.41M-76.99%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Net Premium Revenue Growth Net premiums earned reached $1.41B for nine months, increasing 38.6% driven by member growth.
Membership Base Expansion Average members grew approximately 32% over the nine months period, supporting revenue scale and data insights.
Operating Expense Leverage Adjusted SG&A as percentage of total revenues improved to 16.5% from 20.2% last year.
Cash Flow from Investing Investing activities provided $39.1M net cash, mainly from $139.5M in investment sales and maturities.
リスク要因
Medical Claims Cost Inflation Net medical claims incurred rose 51.3% to $1.15B, outpacing net premium revenue growth rate.
CMS Star Rating Decrease PPO Medicare Advantage plans rating decreased to 3.5 Stars for 2026, impacting future payment year revenue.
Stock-Based Compensation Expense Total stock-based compensation recognized was $78.7M for nine months, contributing to net loss worsening.
Continued Net Loss Net loss from continuing operations totaled $(36.2M) for nine months, worsening by 49.0% versus prior period.
見通し
Counterpart Health SaaS Growth Expanding Counterpart Health SaaS offering to external payors leverages existing AI platform for new revenue streams.
Clover Assistant Adoption Focus Focus remains on increasing adoption of Clover Assistant technology to manage medical loss ratios effectively.
Liquidity Sufficiency Confirmed Management expects current cash, investments, and projected cash flows sufficient for next twelve months obligations.
Future Accounting Standards Company currently evaluating impacts of several new FASB ASUs effective in future fiscal periods.
同業比較
売上高 (TTM)
QDEL$2.73B
TDOC$2.53B
$1.92B
粗利益率 (最新四半期)
BCRX98.4%
GDRX93.2%
NVCR73.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| TWST | $3.01B | -39.2 | -16.6% | 28.8% |
| LFST | $2.73B | -298.4 | -0.6% | 22.0% |
| NHC | $2.63B | 26.0 | 10.0% | 8.1% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
13.8%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年2月26日
EPS:-$0.05
|売上高:$467.06M
財務レポート
財務データ
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年11月7日|売上高: $496.65M+50.1%|EPS: $-0.05+154.0%予想を下回るForm 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年8月8日|売上高: $477.62M+34.1%|EPS: $-0.02-308.0%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年5月9日|売上高: $462.33M+33.3%|EPS: $-0.00-93.5%予想を上回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年3月3日|売上高: $1.37B+8.8%|EPS: $-0.09+80.5%予想を下回るForm 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年11月8日|売上高: $330.99M+8.2%|EPS: $-0.02-79.2%予想通りForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月8日|売上高: $356.26M+11.3%|EPS: $0.01-116.7%予想を上回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月7日|売上高: $346.92M+7.7%|EPS: $-0.04-73.3%予想を上回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年3月14日|売上高: $1.26B+15.0%|EPS: $-0.45+36.6%予想を下回る